Skip to content

Press Release · Press Releases

SK Biopharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for Cenobamate

Issued by PR Newswire

Image: PR Newswire

Application seeks indication for primary generalized tonic-clonic (PGTC) seizures and expansion of existing focal-onset seizure indication to pediatric patients - Submission supported by results from a global Phase 3 trial evaluating the efficacy and safety of cenobamate in patients with...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

Sempra Reports Strong Third-Quarter 2026 Results

Advancing 2026 Value Creation Initiatives Updating 2026 GAAP EPS guidance range Guiding to high-end of 2026 adjusted EPS guidance range Announcing expected 20% increase to Oncor's base capital plan SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Sempra (NYSE: SRE) today reported third-quarter...

PR Newswire ·